Abstract:Fusarium species are saprophytic organisms that are widely distributed in soil and plants. They can cause superficial, invasive, or disseminated fusariosis in immunocompromised and immunocompetent subjects.1Nucci M. Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management.Clin Infect Dis. 2002; 35: 909-920Crossref PubMed Scopus (319) Google Scholar Cutaneous fusariosis is characterized by papulopustular lesions with abscesses, ulcerations, and even necrosis. Most immunocompetent patients with cutaneous fusariosis respond well to antifungal therapy.2Dignani M.C. Anaissie E. Human fusariosis.Clin Microbiol Infect. 2004; 10: 67-75Crossref PubMed Scopus (284) Google ScholarHere we report the case of a 7-year-old girl with cutaneous fusariosis recalcitrant to therapy. Using exome sequencing for this patient, we identified a de novo missense mutation in the signal transducer and activator of transcription 1 (STAT1) gene, the mutation of which was previously known to cause autosomal dominant chronic mucocutaneous candidiasis (CMC).3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google ScholarA 7-year-old Han Chinese girl presented with progressive red verrucous plaques and nodules with ulcerations, exudates, and coarse crusts predominating on her nose, cheeks, right hand, and the inner side of her right knee for more than 6 years (Fig 1, A and B). The lesions were first noticed around her right knee and cheeks after she fell on the floor when she was 11 months old and then involved her right hand 3 years later without traumatic injury.The patient was of full-term normal delivery, with nonconsanguineous marriage of her parents. Family history revealed no members with relevant fungal infectious diseases or immunodeficiencies. She had mild malnutrition and developed normal intelligence. The results of all laboratory examinations, including complete blood count, lymphocyte subsets, serum immunoglobulin levels, and serum complement levels, were normal. Histopathology of the lesions revealed mixed inflammatory cells infiltrating throughout the dermis. Numerous branching hyphae were noted in the stratum corneum with periodic acid–Schiff staining (Fig 1, C). Fusarium solani was isolated from the tissue cultures and identified based on morphologic features (Fig 1, D), and this was further supported by internal transcribed spacer region nucleotide sequencing. On the basis of all the above findings, we made a diagnosis of cutaneous fusariosis caused by F solani.The patient had received different systemic antifungal treatments in the past 5 years, including fluconazol, itraconazole and terbinafine, amphotericin B, and voriconazole. In addition, intramuscular injection of thymopentin, topical antifungal agents, and local heat therapy were also applied since 1.5 years ago, but the lesions were extremely intractable with slow progression.Because of the early onset of the disease and the resistance to antifungal treatment, a genetic defect concerning immune response to fungal infections was hypothesized. Written informed consent was obtained from the parents for molecular genetic studies according to the rules from the Clinical Research Ethics Committee of the Peking University First Hospital.We applied a genome-wide approach and sequenced the exome of the patient (Beijing Genomic Institute, Shenzhen, China). Exome capture was carried out with the SureSelect Human All Exon Kit (Agilent, Santa Clara, Calif), according to the manufacturer's protocols, and then sequenced with the Hiseq2000 platform (Illumina, San Diego, Calif). Single nucleotide variations of the patient were filtered by using the dbSNP134, 1000 Genomes Project, and HapMap8 databases, with 1006 variants left, involving 772 genes. When we compared the data with all the genes reported to be related to fungal infections (see Table E1 in this article's Online Repository at www.jacionline.org),4Romani L. Immunity to fungal infections.Nat Rev Immunol. 2011; 11: 275-288Crossref PubMed Scopus (851) Google Scholar only 1 heterozygous missense mutation c.604A>G (p.M202V) in the STAT1 gene was noted. Sanger sequencing confirmed the STAT1 mutation in the patient. The same variation was not found in her parents, which indicated a de novo mutation (see Fig E1 in this article's Online Repository at www.jacionline.org). This mutation was not detected in 200 ethnically matched healthy control subjects, and the parentage of the patient-parent trio was confirmed by using a panel of microsatellite markers. On the basis of the rarity of de novo mutations (<1 per exome)5Lynch M. Rate, molecular spectrum, and consequences of human mutation.Proc Natl Acad Sci U S A. 2010; 107: 961-968Crossref PubMed Scopus (500) Google Scholar and the previous report of c.604A>G mutation in 3 cases of CMC from 2 kindreds,3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google Scholar this variant was most likely to be the genetic defect underlying the fusariosis in this patient.STAT1, one of the 7 transcription factors of the STAT family and major signaling components of interferon responses, is activated by tyrosine phosphorylation when interferons bind to their receptors.6Najjar I. Fagard R. STAT1 and pathogens, not a friendly relationship.Biochimie. 2010; 92: 425-444Crossref PubMed Scopus (91) Google Scholar By forming a dimer, STAT1 enters the nucleus and triggers the transcription of its targets, which plays a pivotal role in the defense against pathogens. Different types of STAT1 mutations underlie different sets of infectious diseases, including complete or partial STAT1 deficiency with autosomal recessive inheritance in life-threatening or milder intracellular bacterial and viral diseases, autosomal dominant STAT1 deficiency in Mendelian susceptibility to mycobacterial disease, and autosomal dominant gain of STAT1 activity in patients with CMC and autoimmunity.7Boisson-Dupuis S. Kong X.F. Okada S. Cypowyj S. Puel A. Abel L. et al.Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes.Curr Opin Immunol. 2012; 24: 364-378Crossref PubMed Scopus (189) Google Scholar Heterozygous missense mutations in the coiled-coil domain of STAT1 were first reported in 14 patients with autosomal dominant CMC from 5 families by van de Veerdonk et al,8van de Veerdonk F.L. Plantinga T.S. Hoischen A. Smeekens S.P. Joosten L.A. Gilissen C. et al.STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.N Engl J Med. 2011; 365: 54-61Crossref PubMed Scopus (483) Google Scholar who subsequently reported 2 other families with CMC harboring known mutations in a latter publication.9Smeekens S.P. Plantinga T.S. van de Veerdonk F.L. Heinhuis B. Hoischen A. Joosten L.A. et al.STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis.PLoS One. 2011; 6: e29248Crossref PubMed Scopus (91) Google Scholar They demonstrated that patients had deficiencies in mounting TH1 and TH17 responses because of defective IL-12 receptor and IL-23 receptor signaling pathways.Liu et al3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google Scholar reported 12 different heterozygous STAT1 coiled-coil domain missense mutations, including p.M202V, in 47 patients from 20 families with autosomal dominant CMC. All the mutations were shown to be gain-of-function mutations, because of a gain of phosphorylation and a loss of nuclear dephosphorylation. The study found a profound defect in the development of IL-17–producing T cells ex vivo and in vitro. Our patient had some clinical features similar to the patients with CMC, including opportunistic cutaneous fungal infection since infancy and slowly progressive lesions with unsatisfactory therapeutic effect.On the basis of all these studies and findings, it is conceivable that the mutant STAT1 might also function in a dominant-positive manner to predispose our patient to cutaneous fusariosis. It is intriguing that no Candida species infection was experienced in our patient despite its ubiquity in human epithelium, which implicates, in addition to genetic predisposition, that other factors might also be involved in the pathogenic mechanisms. To the best of our knowledge, this is the first report of cutaneous fungal infections other than candidiasis related to STAT1 mutation. Our findings open new doors to understanding genetic predispositions to refractory, early-onset, cutaneous fungal infections. Fusarium species are saprophytic organisms that are widely distributed in soil and plants. They can cause superficial, invasive, or disseminated fusariosis in immunocompromised and immunocompetent subjects.1Nucci M. Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management.Clin Infect Dis. 2002; 35: 909-920Crossref PubMed Scopus (319) Google Scholar Cutaneous fusariosis is characterized by papulopustular lesions with abscesses, ulcerations, and even necrosis. Most immunocompetent patients with cutaneous fusariosis respond well to antifungal therapy.2Dignani M.C. Anaissie E. Human fusariosis.Clin Microbiol Infect. 2004; 10: 67-75Crossref PubMed Scopus (284) Google Scholar Here we report the case of a 7-year-old girl with cutaneous fusariosis recalcitrant to therapy. Using exome sequencing for this patient, we identified a de novo missense mutation in the signal transducer and activator of transcription 1 (STAT1) gene, the mutation of which was previously known to cause autosomal dominant chronic mucocutaneous candidiasis (CMC).3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google Scholar A 7-year-old Han Chinese girl presented with progressive red verrucous plaques and nodules with ulcerations, exudates, and coarse crusts predominating on her nose, cheeks, right hand, and the inner side of her right knee for more than 6 years (Fig 1, A and B). The lesions were first noticed around her right knee and cheeks after she fell on the floor when she was 11 months old and then involved her right hand 3 years later without traumatic injury. The patient was of full-term normal delivery, with nonconsanguineous marriage of her parents. Family history revealed no members with relevant fungal infectious diseases or immunodeficiencies. She had mild malnutrition and developed normal intelligence. The results of all laboratory examinations, including complete blood count, lymphocyte subsets, serum immunoglobulin levels, and serum complement levels, were normal. Histopathology of the lesions revealed mixed inflammatory cells infiltrating throughout the dermis. Numerous branching hyphae were noted in the stratum corneum with periodic acid–Schiff staining (Fig 1, C). Fusarium solani was isolated from the tissue cultures and identified based on morphologic features (Fig 1, D), and this was further supported by internal transcribed spacer region nucleotide sequencing. On the basis of all the above findings, we made a diagnosis of cutaneous fusariosis caused by F solani. The patient had received different systemic antifungal treatments in the past 5 years, including fluconazol, itraconazole and terbinafine, amphotericin B, and voriconazole. In addition, intramuscular injection of thymopentin, topical antifungal agents, and local heat therapy were also applied since 1.5 years ago, but the lesions were extremely intractable with slow progression. Because of the early onset of the disease and the resistance to antifungal treatment, a genetic defect concerning immune response to fungal infections was hypothesized. Written informed consent was obtained from the parents for molecular genetic studies according to the rules from the Clinical Research Ethics Committee of the Peking University First Hospital. We applied a genome-wide approach and sequenced the exome of the patient (Beijing Genomic Institute, Shenzhen, China). Exome capture was carried out with the SureSelect Human All Exon Kit (Agilent, Santa Clara, Calif), according to the manufacturer's protocols, and then sequenced with the Hiseq2000 platform (Illumina, San Diego, Calif). Single nucleotide variations of the patient were filtered by using the dbSNP134, 1000 Genomes Project, and HapMap8 databases, with 1006 variants left, involving 772 genes. When we compared the data with all the genes reported to be related to fungal infections (see Table E1 in this article's Online Repository at www.jacionline.org),4Romani L. Immunity to fungal infections.Nat Rev Immunol. 2011; 11: 275-288Crossref PubMed Scopus (851) Google Scholar only 1 heterozygous missense mutation c.604A>G (p.M202V) in the STAT1 gene was noted. Sanger sequencing confirmed the STAT1 mutation in the patient. The same variation was not found in her parents, which indicated a de novo mutation (see Fig E1 in this article's Online Repository at www.jacionline.org). This mutation was not detected in 200 ethnically matched healthy control subjects, and the parentage of the patient-parent trio was confirmed by using a panel of microsatellite markers. On the basis of the rarity of de novo mutations (<1 per exome)5Lynch M. Rate, molecular spectrum, and consequences of human mutation.Proc Natl Acad Sci U S A. 2010; 107: 961-968Crossref PubMed Scopus (500) Google Scholar and the previous report of c.604A>G mutation in 3 cases of CMC from 2 kindreds,3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google Scholar this variant was most likely to be the genetic defect underlying the fusariosis in this patient. STAT1, one of the 7 transcription factors of the STAT family and major signaling components of interferon responses, is activated by tyrosine phosphorylation when interferons bind to their receptors.6Najjar I. Fagard R. STAT1 and pathogens, not a friendly relationship.Biochimie. 2010; 92: 425-444Crossref PubMed Scopus (91) Google Scholar By forming a dimer, STAT1 enters the nucleus and triggers the transcription of its targets, which plays a pivotal role in the defense against pathogens. Different types of STAT1 mutations underlie different sets of infectious diseases, including complete or partial STAT1 deficiency with autosomal recessive inheritance in life-threatening or milder intracellular bacterial and viral diseases, autosomal dominant STAT1 deficiency in Mendelian susceptibility to mycobacterial disease, and autosomal dominant gain of STAT1 activity in patients with CMC and autoimmunity.7Boisson-Dupuis S. Kong X.F. Okada S. Cypowyj S. Puel A. Abel L. et al.Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes.Curr Opin Immunol. 2012; 24: 364-378Crossref PubMed Scopus (189) Google Scholar Heterozygous missense mutations in the coiled-coil domain of STAT1 were first reported in 14 patients with autosomal dominant CMC from 5 families by van de Veerdonk et al,8van de Veerdonk F.L. Plantinga T.S. Hoischen A. Smeekens S.P. Joosten L.A. Gilissen C. et al.STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.N Engl J Med. 2011; 365: 54-61Crossref PubMed Scopus (483) Google Scholar who subsequently reported 2 other families with CMC harboring known mutations in a latter publication.9Smeekens S.P. Plantinga T.S. van de Veerdonk F.L. Heinhuis B. Hoischen A. Joosten L.A. et al.STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis.PLoS One. 2011; 6: e29248Crossref PubMed Scopus (91) Google Scholar They demonstrated that patients had deficiencies in mounting TH1 and TH17 responses because of defective IL-12 receptor and IL-23 receptor signaling pathways. Liu et al3Liu L. Okada S. Kong X.F. Kreins A.Y. Cypowyj S. Abhyankar A. et al.Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.J Exp Med. 2011; 208: 1635-1648Crossref PubMed Scopus (569) Google Scholar reported 12 different heterozygous STAT1 coiled-coil domain missense mutations, including p.M202V, in 47 patients from 20 families with autosomal dominant CMC. All the mutations were shown to be gain-of-function mutations, because of a gain of phosphorylation and a loss of nuclear dephosphorylation. The study found a profound defect in the development of IL-17–producing T cells ex vivo and in vitro. Our patient had some clinical features similar to the patients with CMC, including opportunistic cutaneous fungal infection since infancy and slowly progressive lesions with unsatisfactory therapeutic effect. On the basis of all these studies and findings, it is conceivable that the mutant STAT1 might also function in a dominant-positive manner to predispose our patient to cutaneous fusariosis. It is intriguing that no Candida species infection was experienced in our patient despite its ubiquity in human epithelium, which implicates, in addition to genetic predisposition, that other factors might also be involved in the pathogenic mechanisms. To the best of our knowledge, this is the first report of cutaneous fungal infections other than candidiasis related to STAT1 mutation. Our findings open new doors to understanding genetic predispositions to refractory, early-onset, cutaneous fungal infections. We thank the patient and her family members for participation in this study. Supplementary data Download .jpg (.16 MB) Help with files Fig E1 Download .doc (.28 MB) Help with doc files Table E1 Download .jpg (.16 MB) Help with files Fig E1 Download .doc (.28 MB) Help with doc files Table E1

Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib

STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors

Immunophenotyping and Therapeutic Insights from Chronic Mucocutaneous Candidiasis Cases with STAT1 Gain-of-Function Mutations

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation

Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation

Dysregulated STAT1 Gain-of-function: Pathogen-free Autoimmunity and Fungal Infection

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Qualitative Immunoglobulin Deficiency Causes Bacterial Infections in Patients with STAT1 Gain-of-Function Mutations

Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF

Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome

STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders

Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation

Genetic and Functional Identifying of Novel STAT1 Loss-of-Function Mutations in Patients with Diverse Clinical Phenotypes

Novel STAT1 mutation in a paediatric case of chronic mucocutaneous candidiasis complicated by primary hypothyroidism: clinical presentation, genetic analysis and prognostic implications

Chinese Pedigree of Chronic Mucocutaneous Candidiasis Due to STAT1 Gain-of-Function Mutation: A Case Study and Literature Review

Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma

Chronic mucocutaneous candidiasis with STAT1 gain-of-function variant: a case report and review of the literature

Exome Sequencing Reveals a Signal Transducer and Activator of Transcription 1 (STAT1) Mutation in a Child with Recalcitrant Cutaneous Fusariosis